System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Research Support, Non-U.S. Gov't Epublish 7 citations

PubMed: 38550597 DOI: 10.3389/fimmu.2024.1328781

Metabolism-driven glycosylation represents therapeutic opportunities in interstitial lung diseases.

Front Immunol 15:1328781

Authors: Katarzyna Drzewicka, Zbigniew Zasłona

Affiliations

  • Molecure SA, Warsaw, Poland.

Abstract

Metabolic changes are coupled with alteration in protein glycosylation. In this review, we will focus on macrophages that are pivotal in the pathogenesis of pulmonary fibrosis and sarcoidosis and thanks to their adaptable metabolism are an attractive therapeutic target. Examples presented in this review demonstrate that protein glycosylation regulates metabolism-driven immune responses in macrophages, with implications for fibrotic processes and granuloma formation. Targeting proteins that regulate glycosylation, such as fucosyltransferases, neuraminidase 1 and chitinase 1 could effectively block immunometabolic changes driving inflammation and fibrosis, providing novel avenues for therapeutic interventions.

MeSH

Immune System Diseases, Lung Diseases, Interstitial, Sarcoidosis, Macrophages, Therapeutics, Fibrosis

Cited by